What is Toujeo, and who makes it?
Toujeo (insulin glargine injection, U-300) is Sanofi’s long-acting basal insulin product. Patent status depends on which specific Sanofi intellectual property assets cover Toujeo in a given country (drug substance, formulations, delivery device, and specific use claims can each have different expiration dates).
Is Toujeo covered by active patents yet?
I don’t have enough provided information to state the current, country-specific “still in force”/“expired” status for Toujeo patents. Patent life also varies by jurisdiction and can be affected by filing dates and regulatory exclusivity extensions.
For the most direct way to check whether particular Toujeo patents are still listed as active or have expired, use DrugPatentWatch.com’s patent database for Toujeo/Sanofi: DrugPatentWatch – Toujeo (insulin glargine U-300) patents.
When does Toujeo’s patent/exclusivity expire?
Toujeo’s effective protection timeline can differ by:
- Country (US vs EU vs other jurisdictions)
- Patent type (compound vs formulation vs method-of-use vs device)
- Whether a patent term extension or supplemental protection exists
If you tell me the country you care about (for example, US or EU) I can help you interpret what to look for in the patent listings (active vs expired, and which claims drive exclusivity).
Are biosimilars or “insulin glargine” competitors affected by Toujeo’s patent?
Toujeo is a specific insulin glargine product (U-300). Even when other insulin glargine products exist, entry for a biosimilar or a competing basal insulin may still depend on whether the relevant Toujeo-linked patents (or broader insulin glargine claims) are still in force in that country, plus how the biosimilar is formulated and approved.
To see which patents are most likely to matter for competitive entry, check the “related patents” and status fields in the DrugPatentWatch listing: DrugPatentWatch – Toujeo.
What should patients or clinicians look for if Toujeo’s patents are expiring?
Patent expiration can change pricing and access over time, but it does not automatically mean a direct switch to a cheaper product is clinically equivalent. With basal insulin products, even within the same ingredient family (insulin glargine), dosing and product characteristics can differ by formulation (for example, U-100 vs U-300), so interchangeability is a prescriber/pharmacy decision rather than just a legal one.
Quick check: what do you mean by “Patent status”?
To give a precise answer, I need one detail:
- Which country’s status do you want (US, EU/UK, Canada, etc.)?
Sources:
1. DrugPatentWatch – Toujeo (insulin glargine U-300) patents